Skip to Content

MultiCell Technologies Inc MCET

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MCET is trading at a 490% premium.
Price
$0.00
Fair Value
$7.41
Uncertainty
Extreme
1-Star Price
$2.82
5-Star Price
Economic Moat
Ymqd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MCET is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.00
Market Cap
$5,000.95
Volume/Avg
10,000 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company’s medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
2

Valuation

Metric
MCET
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
MCET
Quick Ratio
0.18
Current Ratio
0.19
Interest Coverage
−102.18
Quick Ratio
MCET

Profitability

Metric
MCET
Return on Assets (Normalized)
−212.38%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
MCET
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QdnzyghlfWqbj$625.5 Bil
Vertex Pharmaceuticals Inc
VRTX
GzpwjpqPddgfx$127.0 Bil
Regeneron Pharmaceuticals Inc
REGN
HclyfqbMmkfd$119.0 Bil
Moderna Inc
MRNA
ZyshrgsGlzj$47.1 Bil
Alnylam Pharmaceuticals Inc
ALNY
CzcnxpgGjqbxh$33.0 Bil
argenx SE ADR
ARGX
QmnrnnrzqTktq$27.7 Bil
BioNTech SE ADR
BNTX
NwrzyhscCdrdw$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
XkhbgpnGjrszk$15.9 Bil
United Therapeutics Corp
UTHR
KhrhvvbncMgdd$14.4 Bil
Incyte Corp
INCY
KqsxlfjrDdfgvr$12.3 Bil

Sponsor Center